Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Dendreon’s Los Angeles Cancer Immunotherapy Manufacturing Facility

By Pharmaceutical Processing | June 30, 2011

Dendreon Corporation has announced that the FDA approved its
Los Angeles cancer immunotherapy manufacturing facility, allowing the company
to continue to increase the availability of PROVENGE® (sipuleucel-T) across the
U.S. to help meet the needs of patients with asymptomatic or minimally
symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
 

 

The Los Angeles
facility includes 36 workstations, and Dendreon will bring these new workstations
online in a staged approach. With this FDA approval and the fully approved New Jersey facility,
Dendreon now has total of 84 workstations available to manufacture PROVENGE.
Dendreon expects to continue to provide additional capacity through the anticipated
licensure mid-year of one other manufacturing facility in the United States.
 In April, Dendreon filed a post-approval supplement for its third
facility in Atlanta,
for which there is an FDA action date of August 28, 2011.

 

PROVENGE is designed to induce an immune response against
prostatic acid phosphatase (PAP), an antigen expressed in most prostate
cancers, and is the first in a new therapeutic class of drugs known as
autologous cellular immunotherapies.

 

“As the foundation of care, PROVENGE is an important
treatment option for men with metastatic castrate resistant prostate
cancer,” said Mitchell H. Gold, M.D., president and chief executive
officer of Dendreon. “The FDA approval of the Los Angeles facility will enhance our ability
to provide PROVENGE to the many patients across the country who may benefit
from it.”  

 

In anticipation of the availability of the additional
workstations, Dendreon expects to have approximately 225 active infusing sites
by the end of the second quarter and approximately 500 by the end of 2011.

 

 

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards